novo nordisk's wegovy reduces cardiovascular risk more than lilly's tirzepatide Why weight-loss drug shows promise for heart disease Novo weight-loss drug may preserve

Many describe it as less uncomfortable than a blood draw or flu shot

Tirzepatide and dyspepsia (indigestion) Dyspepsia a feeling of uncomfortable fullness, burning, or pressure in the upper abdomen after eating shows up in 58% of people on tirzepatide

By targeting both, Tirzepatide offers a dual mechanism that enhances insulin response and supports sustainable weight loss

However, weight-loss drugs are included in a small group of drugs that can be excluded from coverage 1 (though the statutory exception refers to agents used for weight loss, obesity drugs is used to refer to this group of medications in this analysis)

Bring your ID and insurance card to your appointment

Semaglutide deep-dive Semaglutide is sold under three brand names, all manufactured by Novo Nordisk: Ozempic -- weekly injection, FDA-approved for type 2 diabetes (doses 0.25 mg, 0.5 mg, 1 mg, 2 mg) Wegovy -- weekly injection, FDA-approved for chronic weight management in 2021 (doses up to 2.4 mg) [3] Rybelsus -- daily oral tablet, approved for type 2 diabetes For weight loss specifically, Wegovy is the on-label choice